The mechanism of bFGF-induced cell death in tumours of the Ewing's sarcoma family (ESFT) has been investigated. bFGF-induces phosphorylation of FGFr 1 and activation of Ras/ERK in ESFT cells that die when exposed to bFGF. Induction of cell death was associated with activation of both initiator (caspases-2, -8 and -10) and eector (caspases-3, -6 and -7) caspases. Moreover, the general caspase inhibitor Z-VAD-FMK protected cells from bFGF-induced cell death. After treatment with bFGF, a loss of mitochondrial transmembrane potential was accompanied by down-regulation of Bcl-2. However, the observed cell death was not associated with release of cytochrome c from the mitochondria. Furthermore, expression of wild-type p53 was not required for bFGF-induced cell death. These observations suggest that bFGF-induced cell death may be mediated through a cell death receptor mechanism, supported by up-regulation of the p75 neurotrophin receptor. bFGF-induced cell death was associated with up-regulation of p21 and p53, down-regulation of PCNA and cyclin A and a decrease in active pRb1, changes consistent with accumulation of cells in G1. These data demonstrate that bFGF-induced cell death is eected through a caspase-dependent and p53-independent mechanism, that may be mediated through a cell death receptor pathway.
Introduction
Basic ®broblast growth factor (bFGF) is a potent mitogen for a number of dierent cell types (Joy et al., 1997; Piotrowicz et al., 1997; Kusaka et al., 1998) , and over-expression of the growth factor and its receptors has been implicated in transformation and malignant progression (Yamaguchi et al., 1994; Mason, 1994) . Therefore the use of bFGF to treat malignancy would appear counterintuitive. However, we have recently shown treatment of NuNu mice with bFGF decreases the growth of highly tumourgenic ESFT xenografts (Sturla et al., 2000) . This decrease in xenograft growth was associated with an increase in apoptotic cell number and a decrease in proliferation index. These observations are consistent with our own in vitro ®ndings, and those of others in the ESFT cell lines SK-ES1 (Schweigerer et al., 1987) and SK-N-MC (Smits et al., 2000) , and in the breast cancer cell line MCF-7 (Wang et al., 1997) .
bFGF signal transduction occurs through a family of high and low anity FGF receptors. The four high anity tyrosine kinase receptors share the same basic structure, each with an intracellular split-kinase domain and an extracellular domain containing up to three immunoglobulin-like domains; modi®ed ligand binding and subcellular localization can aect the activity of these receptors. All four FGF receptor subtypes are expressed in ESFT cells, whether they die when exposed to bFGF or not (Sturla et al., 2000 and unpublished observations) . Consequently bFGF-induced cell death is not associated with expression of a speci®c FGF receptor type that has already been characterized, although an as yet unidenti®ed FGF receptor, distinct pattern of receptor expression or novel receptor signalling cascade may confer growth inhibitory eects.
The induction of cell death by bFGF may be exploited to modulate the behaviour of ESFT, and provide an opportunity for therapeutic initiatives. Whether bFGF itself will be useful clinically is not yet clear, although understanding its mechanism of action may identify novel targets for the modulation of ESFT behaviour. Furthermore a recent study has suggested bFGF increases ESFT proliferation in serum-depleted conditions, and that this eect may be linked to expression of the EWS-ETS gene rearrangement characteristic of the ESFT (Girnita et al., 2000) . Therefore for the ®rst time we have analysed the eect of bFGF on three cell lines with dierent genotypes (representing those most frequently found in ESFT), and subsequently investigated its mechanism of action.
Results
Decreased ESFT cell number is mediated by bFGF-induced cell death bFGF decreased viable cell number in TC-32 (P50.01) and TTC-466 (P50.01) cells (Figure 1a ). This eect was dose dependent, bFGF at 10 ± 40 ng/ml having maximal eect (results not shown). By electron microscopy, both apoptotic and necrotic cells were identi®ed after treatment with bFGF (10 ng/ml) ( Figure 1b) . Apoptotic cells showed typical margination of the chromatin and chromatin condensation; cells were smaller and more electron-dense. The nuclear and plasma membranes remained intact, with the subsequent formation of apoptotic bodies ( Figure  1b) . However, a cell population with an intact nuclear membrane and chromatin margination, but with plasma membrane permeability, increased cytoplasmic volume and a loss of cellular organelles was also observed (Figure 1b) .
Fluorescence activated cell sorter analysis (FACScan), sorting for annexin V-and PI-labelled cells, identi®ed three cell populations: one labelling with annexin V alone, one with PI alone and one with both annexin V and PI ( Figure 1c ). In exponentially growing control TC-32, TTC-466 and A673 cells, 87% or more of the cell population was viable and did not label with PI or annexin V (Figure 1c, controls) . However 48 h after treatment with bFGF 50% of TC-32 and 25% of TTC-466 cells labelled with annexin V, PI or both, suggesting they were either apoptotic or dead. In the TC-32 cells 24% were alive but apoptotic (labelled with annexin V alone) and 26% were dead (labelled with annexin V plus PI or with PI alone); in the TTC-466 cells 24% of the cells were dead and 1% apoptotic. The greatest eect of bFGF on TTC-466 cells was at 72 h, when 47% of the cells were dead (labelled with annexin V and PI or with PI alone; Figure 1c ). At 72 h no TC-32 or TTC-466 cells labelled with annexin V alone, there were few viable cells and a large amount of cell debris.
bFGF had no eect on cell number, ultrastructure or labelling with annexin V or PI in the A673 ESFT cells (Figure 1a ± c).
bFGF-induces phosphorylation of FGFr1 immunoprecipitated proteins and activation of Ras and ERK
Exposure of TC-32 cells to bFGF (10 ng/ml) induced rapid phosphorylation of the FGFr1 protein (approximate size 190 kD) and a smaller molecular weight protein (90 kD) of uncon®rmed identity (Figure 2 ). The size of the lower molecular weight protein is consistent with that of the FGF docking protein FRS2, (a) (b) implicated in the transmission of extra-cellular signals from the FGFr's to the Ras/ERK signalling cascade (Ong et al., 2000) . Activation of Ras and phosphorylation of ERK was detected within 5 min exposure to bFGF (Figure 2) , consistent with the hypothesis that bFGF-induces cell death through a Ras/ERK activated pathway. Whether this is necessary for the induction of cell death in ESFT cells requires further investigation.
bFGF-induced cell death is mediated through a caspase dependent mechanism.
TC-32 (49%) and TTC-466 (33%) cells were protected from bFGF-induced cell death when treated with the general caspase inhibitor Z-VAD-FMK (10 mM) (Figure 3a) . This protective eect was signi®cant (P50.01) in TC-32 and TTC-466 cells after 24 or 48 h treatment with bFGF (10 ng/ml). FACScan¯ow cytometry for CaspaTag and PI labelled cells identi®ed three populations: one labelling with CaspaTag alone, one with only PI, and one with both CaspaTag and PI ( Figure 3b ). Under normal growth conditions 85% or more of the TC-32 and TTC-466 cell population did not label with CaspaTag or PI. However, 48 h after treatment with bFGF (10 ng/ml) 14% of TC-32 and 4% of TTC-466 cells were viable but expressed activated caspases (labelled with CaspaTag alone) ( Figure 3b ). This is compared to 49% of TC-32 and 19% of TTC-466 cells that were dead (labelling with CaspaTag plus PI or with PI alone) ( Figure 3b , Table  1 ). No change in caspase activity was observed in A673 cells after treatment with bFGF (10 ng/ml) (Figure 3a , b, Table 1 ). Caspase activity was assayed using the chromophore para-Nitroaniline (pNa) attached to a speci®c caspase substrate sequence. Cleavage of the substrate results in the release of the chromogen, indicating activation of a speci®c caspase. After 48 h treatment of TC-32 and TTC-466 cells with bFGF (10 ng/ml), caspase-2 (Ac-VDVAD-pNA) and -8 (Ac-IETD-pNA) were signi®-cantly activated (P50.01 and P50.05 respectively) compared to controls ( Figure 3c ; Table 2 ). However, Ac-VEID-pNA and Ac-DEVD-pNA were also signi®-cantly cleaved in the TC-32 cell line after treatment with bFGF (10 ng/ml) for 48 h (P50.01) ( Table 2) . This is consistent with activation of caspase-6, and Figure 1 bFGF-induces cell death in TC-32 and TTC-466 but not A673 ESFT cells. (a) TC-32 and TTC-466 viable cell number was decreased after treatment with bFGF (10 ng/ml) for 24 ± 72 h. bFGF had no eect on A673 cell number. Cells were harvested by trypsinization and viable cell number counted using Trypan blue and a Neubauer haemocytometer. Viable cell number is presented as mean+s.e.m. Statistical analysis was performed using ANOVA, followed by Dunnett's multiple comparison post-hoc test between treated and untreated samples. *P50.01.
=Control &=10 ng/ml bFGF T=20 ng/ml bFGF~=40 ng/ml bFGF. (b) Cell death was characterized by electron microscopy; / necrotic cells (breakdown of plasma membrane, increased cytoplasmic volume, vacuolation and organelle destruction), / apoptotic cells (intact nuclei and chromatin magination). Cells were harvested after 48 h treatment with bFGF (20 ng/ml) and subsequently ®xed (2.5% (v/v) gluteraldehyde in Sorenson's buer), dehydrated (graded series of ethanol (70 ± 100%)) and in®ltrated (araldite/propylene oxide (1 : 1)) before being mounted. Magni®cation 61500. (c) The number of dead cells was increased after exposure to bFGF (20 ng/ml) for 48 ± 72 h. Cells were harvested at 24 h intervals and cell death determined by the detection of annexin V and PI labelling using the FACscan¯ow cytometer. Phosphotidylserine (externalized on cell membranes early in apoptosis) was detected by labelling with annexin V, and plasma cell membrane integrity by Pl. Results presented are representative of three individual experiments. Analysis was undertaken using CellQuest TM software. The x-axis (FL1-H) represents labelling with annexin v, and the y-axis (FL2-H) propidium iodide. Lower left quadrant=live cells; lower right quadrant=early apoptotic cells (annexin V positive); upper left quadrant=dead necrotic cells (propidium iodide positive); upper right quadrant=dead apoptotic cells (annexin V and propidium iodide positive) possibly one or more of caspases-3, -7, -8 or -10 (Figure 3c ). At 72 h post-bFGF (10 ng/ml) treatment Ac-DEVD-pNA remained cleaved in both responsive cell lines (TC-32, P50.05 and TTC-466, P50.01) ( Table 2 ); in the TC-32 cells Ac-VDVAD-pNA was also cleaved (P50.05) ( Figure 3c ) consistent with activation of caspase-2. Cleavage of the Ac-LEHDpNA substrate (caspase-9) was not observed after treatment with bFGF (10 ng/ml) in any of the cells studied ( Figure 3c , Table 2 ). No change in substrate cleavage was observed in A673 cells after treatment with bFGF (10 ng/ml) for up to 72 h ( Figure 3c ; Table  2 ). Cleavage of caspase 8 was con®rmed by Western blot analysis (Figure 3d ). (Table 4) . A second lower molecular weight protein of approximately 90 kD was also phosphorylated after exposure of cells to bFGF; the size of this protein is consistent with that of the FGF docking protein FRS2. Expression of FGFr 1 protein was the same in treated and untreated cells. After 2 min exposure to bFGF levels of Ras-GTP were increased, consistent with Ras activation. Active Ras was extracted from cell lysate by anity precipitation with GST-RBD, separated by 15% SDS ± PAGE and detected by immunoblotting with antibodies to pan-Ras. Comparable levels of total Ras were detected in treated and untreated lysates (results not shown). Immunoblotting with antibodies against pan-ERK in unstimulated TC-32 cells identi®ed the 42 kDa protein (ERK). ERK in TC-32 cells was phosphorylated after treatment with bFGF for 2 ± 10 min, as demonstrated by a shift in ERK mobility (ERK.P). Cell lysate was analysed for a mobility shift by immunoblotting with antibodies to pan-ERK following separation of proteins by lowbis 15% SDS ± PAGE (d) Figure 3 Induction of cell death by bFGF is dependent on activation of caspases. (a) TC-32, TTC-466 and A673 cells were treated with bFGF (10 ng/ml), Z-VAD-FMK (10 mM) or bFGF (10 ng/ml)+Z-VAD-FMK (10 mM) for 24, 48 and 72 h. Cells were harvested at each time point and viable cell counts carried out using the Trypan blue exclusion assay (0.1%). Z-VAD-FMK (10 mM) had no eect on viable cell number alone. Viable cell number is presented as mean+s.e.m. Statistical analysis was performed using ANOVA, followed by Dunnett's multiple comparison post-hoc test at each time point between bFGF (10 ng/ml) treated and bFGF (10 ng/ml)+Z-VAD-FMK (10 mM) treated samples (*P50.01).~Control; T Z-VAD-FMK;^bFGF (10 ng/ml); & bFGF (10 ng/ml)+Z-VAD-FMK. (b) TC-32, TTC-466 and A673 cells were treated with bFGF (10 ng/ml) for 48 h. Cells were harvested and incubated with CaspaTag (Z-VAD-FMK 10 mM) for 45 min. PI was added immediately before FACScan analysis. Bcl-2 levels are decreased in cells after bFGF-induced cell death Expression of Bcl-2 protein was decreased in TC-32 and TTC-466 cells after treatment with bFGF (10 ng/ml) for 48 and 72 h compared to control, untreated cells ( Figure  4a ). Bax protein levels were relatively unchanged in bFGF (10 ng/ml) treated cells (Figure 4b ). Furthermore, Bcl-2 and Bax protein expression was unchanged in A673 cells after treatment with bFGF (10 ng/ml) (Figure 4a, b) . Previous studies have shown high levels of Bcl-2 protect some cells from cell death (Reed, 1998) . However, the levels of Bcl-2 were similar in both ESFT cells that do not die when exposed to bFGF (A673 and SK-ES 1) and those that die (TC-32, TTC-466, SK-N-MC and RD-ES) (Figure 4c ).
bFGF-induced cell death in ESFTs is not accompanied by cytochrome c release from mitochondria
After treatment of TC-32 or TTC-466 cells with bFGF (10 ng/ml) for 48 h, an increase in¯uorescence of tetra-methylrhodamine ethyl ester percholate (TMRE) was observed compared to untreated controls (8 to 25% and 13 to 40% respectively) ( Figure 5a ). This increase in¯uorescence re¯ects a greater proportion of cells with TMRE outside the mitochondria, consistent with a loss of mitochondrial transmembrane potential (DC m ). Moreover, this was shown to be signi®cant at 24, 48 and 72 h post-bFGF (10 ng/ml) treatment in the TC-32 ( Figure 5b ) and TTC-466 (results not shown) cells. In the A673 cells there was no dierence in TMRE distribution between control (4%) and treated (10 ng/ml bFGF) (5%) cells (Figure 5a ).
After cellular fractionation of TC-32, TTC-466 and A673 cell protein extracts, Western blot analysis using a cytochrome c mouse monoclonal antibody demonstrated a mitochondrial rich (M) and a non-mitochondrial rich (cellular cytosol) (C) fraction. Cytochrome c was detected only in the mitochondrial fraction ( Figure  5c ), demonstrating speci®c cellular fractions and intact mitochondria. Furthermore, cytochrome c protein expression was detected in the mitochondrial fraction, but not the cytosolic fraction after treatment of TC-32 (Figure 5c ), TTC-466 and A673 cells with bFGF (10 ng/ml). Table 1 The percentage of CaspaTag positive (alive or dead cells with activated caspases), propidium iodide (dead cells with or without activated caspases) and label free (alive) ESFT cells after exposure to bFGF (10 ng/ml) for 24 (a), 36 (b), 48 (c) and 72 (d) h. One-way ANOVA was undertaken at each time point followed by Dunnett's multiple comparison post-hoc test between treated and untreated samples 
bFGF-induced cell death in ESFTs is not dependent on wild-type p53
Induction of cell death by bFGF (10 ng/ml) in TC-32 and TTC-466 cells was accompanied by up-regulation of p53 ( Figure 6a ). Moreover, p53 was not expressed in control or bFGF (10 ng/ml) treated A673 cells. Five out of six of the ESFT cell lines examined (TTC-466, SK-N-MC, RD-ES, SK-ES 1 and A673) demonstrated mutations in the p53 gene, irrespective of whether the cells died when exposed to bFGF (10 ng/ml) or not (Table 3) . However, the mutations identi®ed in TTC-466 cells are reported to be relatively common polymorphisms, and so are unlikely to be deleterious to p53 function. Expression of p53 protein was high in TTC-466, RD-ES and SK-ES 1 cells compared to the level in TC-32 cells (Figure 6b) , consistent with the hypothesis that TTC-466, RD-ES and SK-ES 1 cells express mutated p53 (Bartek et al., 1990) . The SK-N-MC cell line did not express p53 at the protein level, re¯ecting the massive deletion involving exons 2, 3 and 4 of this gene (Table 3) . However this ESFT cell line did die when exposed to bFGF (10 ng/ml) (Sturla et al., 2000) , demonstrating that p53 is not essential for the induction of cell death by bFGF.
Expression of the p75 neurotrophin receptor is up-regulated after exposure of TC-32 cells to bFGF
Treatment of TC-32 cells with bFGF (10 ng/ml) induced expression of the cell death receptor p75 after 24 h exposure ( Figure 7 ). This suggests that bFGFinduced cell death may be mediated through a cell death receptor pathway, although this requires further investigation.
bFGF disrupts progression through G 1 /S of the cell cycle Cells were synchronized by serum starvation (0.5% FCS for 48 h) (Westwood, PhD thesis 2001). FACScan ow cytometry on cells labelled with PI was used to examine their DNA content, allowing subsequent analysis of cell cycle phase. After 48 h (TC-32) or 72 h (TTC-466) treatment with bFGF (10 ng/ml) cell cycle pro®le was changed, with only 45% of the cell populations remaining in the G 1 phase (Figure 8a) .
Involvement of the G 1 checkpoint after treatment with bFGF (10 ng/ml) was con®rmed by Western blotting for proteins associated with the G 1 or S phases of the cell cycle. Phosphorylation of the retinoblastoma protein (pRb1) was decreased in TC- TC-32, TTC-466 and A673 cells treated with bFGF (10 ng/ml) for 24, 48 or 72 h, and cell lysates prepared from treated and untreated cells. Lysates were separated by SDS ± PAGE, transferred to nitrocellulose solid support and immunoblotted for Bcl-2 (a) or Bax (b). Silver stain was used to con®rm protein loading (results not shown in a and b), and immunoblotting controls with no primary antibody were also carried out to con®rm the speci®city of the antibodies (not shown). The results are representative of three separate experiments. Bcl-2+ve control=Jurkatt cell lysate; Bax+ve control=Human foreskin ®broblasts; Bcl-2 and Bax7ve control=Rama temporaria skeletal tissue 32 cells after treatment with bFGF (10 ng/ml) for 48 h (Figure 8b ). Down-regulation of proliferating cell nuclear antigen (PCNA) also occurred 48 h after treatment with bFGF (10 ng/ml) (Figure 8b ).
The cellular levels of p21 were dramatically increased in TC-32 cells after treatment with bFGF for 48 and 72 h (Figure 8b ). Furthermore cyclin A, an S phase speci®c cyclin, was down-regulated in the TC-32 cell line (Figure 8b ) after treatment with bFGF (10 ng/ml) for 48 and 72 h. bFGF (10 ng/ml) had the same eect on these cell cycle speci®c proteins in the responsive TTC-466 cell line (results not shown). However, no eect on cell cycle pro®le, phosphorylation status of pRb1 or protein levels of PCNA and cyclin A in A673 cells was observed after bFGF (10 ng/ml) treatment (Figure 8a, b) .
Discussion
Treatment of the TC-32 and TTC-466 ESFT cell lines with bFGF produced a decrease in viable cell number, which correlated with an increase in cell death consistent with our previous observations (Sturla et al., 2000) . The induction of cell death by bFGF appears not to be dependent on EWS-ETS gene rearrangement type; bFGF induced death in cells with an EWS-FLI1 type 1 (TC-32) or an EWS-ERG (TTC-466) fusion. Both the bFGF-resistant A673 and -responsive TC-32 cells have an EWS-FLI1 type 1 gene fusion. Our previous studies have shown induction of death in EWS-FLI1 type 2 containing RD-ES cells (Sturla et al., 2000) . Furthermore, bFGF decreases cell proliferation (Wang et al., 1997; Johnson et al., 1998) and induces cell death (Burchill, unpublished observation) in the breast cancer cell line MCF7, which does not contain an EWS-ETS gene rearrangement (Burchill, unpublished observations). These observations are consistent with the hypothesis that EWS-ETS fusion protein is not involved in the mechanism of bFGF-induced cell death. In direct contrast to this study, it has been reported that activation of the bFGF pathway may be important for the maintenance of a malignant phenotype in RD-ES ESFT cells, possibly by up-regulating expression of the EWS-FLI1 protein (Girnita et al., 2000) . However these eects were only observed in serum-depleted conditions after 24 h exposure to bFGF, and may equally re¯ect bFGF-induced survival of RD-ES cells under low serum conditions. Our own studies have shown that in the presence or absence of serum cell death is apparent 48 and 72 h after initial exposure to bFGF; Girnita et al. (2000) did not report on the eect Mechanism of bFGF-induced cell death G Westwood et al Figure 5 Mitochondrial transmembrane potential and cytochrome c. TC-32, TTC-466 and A673 cells were treated with bFGF (10 ng/ml), and pulsed with TMRE (50 nM) for 30 min prior to cell harvest using a cell scraper. Cells (1610 6 cells/ml) were resuspended in PBS supplemented with 15 nM TMRE, and mitochondrial transmembrane potential determined immediately by¯ow cytometry and CellQuest TM software. (a) Cells were treated with bFGF (10 ng/ml) for 48 h. Percentages represent the proportion of cells labelled with TMRE. Histograms are representative of four individual experiments. &=Control; &=bFGF (10 ng/ml). FL1-H=TMRE. (b) Cells were treated with bFGF (10 ng/ml) for 24, 48 or 72 h. The percentage of cells labelled with TMRE (representing a loss of mitochondrial transmembrane potential) is presented as mean+s.e.m. (n=4). Statistical analysis was performed using ANOVA, followed by Dunnett's multiple comparison post-hoc test *P50.05; **P50.01. &=Control; &=bFGF (10 ng/ml). (c) TC-32 cells were homogenized and separated by centrifugation (see text) to produce a mitochondrial (M) and a cytoplasmic (C) fraction. The identity of these fractions was con®rmed by separation of each (10 mg of protein) using SDS ± PAGE and immunoblotting for cytochrome c (15 kDa). Cells were untreated or treated with bFGF (10 ng/ml) for 24, 48 or 72 h before homogenization and fractionation. Gels were stained with silver stain to con®rm the quality of extracts and equal protein loading. The positive control (+ve) represents total protein lysates of bFGF on RD-ES cells beyond 24 h. It is of course possible that the RD-ES cells used in the experiments of Girnita et al. (2000) and those in our own experiments represent dierent clonal populations of the original tumour from which the RD-ES cells were established, explaining our dierent observations. Whilst we cannot currently exclude the possibility that bFGF may eect a change in the expression of EWS-ETS fusion transcripts in ESFT cells, it is clear this is not essential for the induction of cell death by bFGF (data in breast cancer cells) and the type of EWS-ETS fusion transcript does not de®ne which ESFT cells die when exposed to bFGF.
bFGF-induced death is mediated, at least in part, through a caspase dependent mechanism. This is supported by the protection of ESFT cells from cell death by incubation with the general caspase inhibitor Z-VAD-FMK, and caspase cleavage after exposure to bFGF. Previous studies have suggested that caspases sensitive to Z-VAD-FMK target Bax to the mitochondria (Goping et al., 1998) where Bax is reported to induce cell death . This is thought to result in the release of cytochrome c from mitochondria, which subsequently complexes with Apaf-1 in the cytoplasm (in the presence of ATP) to form the socalled apoptosome. This complex activates cytosolic procaspase-9, inducing a downstream death programme by cleavage of key intracellular targets (Cryns and Yuan, 1998) . Levels of Bax protein were unchanged following treatment with bFGF suggesting it may not play a major role in the induction of cell death by bFGF, although we cannot exclude the possibility that Bax might be translocated to the mitochondria where it initiates release of other pro-apoptotic proteins. However bFGF-induced cell death was not accompanied by activation of the initiator caspase procaspase-9, consistent with the hypothesis that bFGF-induced cell death is not mediated by the release of cytochrome c from mitochondria.
Induction of cell death by bFGF did however activate the initiator caspases-2, -8 and -10, which are most frequently cleaved by members of the TNF Figure 6 Expression of p53 is not essential for induction of cell death by bFGF, although it may play a role in the death cascade when it is expressed. (a) TC-32, TTC-466 and A673 cells were untreated or treated with bFGF (10 ng/ml) for 24, 48 or 72 h before being lysed. Cell lysates were separated by SDS ± PAGE and p53 was detected by immunoblotting. Blots are representative of three independent experiments. Immunoblotting controls were also carried out with no primary antibody (results not shown). Gels were stained with silver stain to demonstrate equal quality and loading of protein lysates (total protein shown for A673 cells). Treatment of TC-32 and TTC-466 cells with bFGF for 72 h resulted in an increased level of p53 expression compared to control untreated cultures; A673 cells did not express p53.+ve control=Human foreskin ®broblasts; 7ve control=Rama temporaria skeletal tissue. (b) TC-32, TTC-466, RD-ES and SKES-1 cells all express p53 protein; SK-N-MC and A673 cells do not. Interestingly SK-N-MC cells do not express p53 protein but do die when exposed to bFGF, consistent with the hypothesis that p53 is not essential for the induction of cell death by bFGF. Blots are representative of three independent experiments. The silver stain gel demonstrates equal loading of protein lysates. Immunoblotting controls were also carried out with no primary antibody (results not shown) Figure 7 Expression of the p75 neurotrophin receptor was upregulated after treatment of TC-32 cells with bFGF. TC-32 cells were either untreated or treated with bFGF (10 ng/ml) for 24 ± 72 h, after which cells were harvested, lysed and size separated by SDS ± PAGE. Proteins were transferred onto nitrocellulose and immunoblotted for the p75 neurotrophin receptor. After treatment with bFGF for just 24 h an upregulation in p75 protein level was identi®ed; expression of the intracellular signalling protein ERK was used as a control. +c=HS294T cell lysate superfamily of receptors. The receptors in this family are divided into those without and those with a socalled death-domain (Tartaglia et al., 1993; Itoh and Nagata, 1993) and convey either a survival or death signal respectively (Baker and Reddy, 1998) . The time course of bFGF-induced death and activation of caspase-8, a key eector of cell death receptor mediated apoptosis (Bratton et al., 2000; Schneider and Tschopp, 2000; Kruidering and Evan, 2000) , is consistent with the hypothesis that bFGF-induced cell death is mediated by up regulation and/or activation of cell death receptors. Previous studies have shown ESFT cell lines are induced to die through CD95 FAS (Kontny et al., 1998) and TRAIL (Kumar et al., 2001) dependent mechanisms. Consequently transcriptional regulation of death receptors such as CD95 FAS (OwenSchaub et al., 1995; Schneider and Tschopp, 2000; Krammer, 2000) , TRAIL-R (Walczak and Krammer, 2000) or KILLER/DR5 (Wu et al., 1997) may eect cell death in ESFT cells following exposure to bFGF. In this study, expression of the neurotrophin receptor p75, which belongs to the TNF receptor superfamily, is up-regulated following exposure to bFGF. This implicates the pro-apoptotic activity of p75 in bFGFinduced cell death, although the molecular mechanisms of p75 signalling remain to be fully characterized. Recent studies have shown that p75-induced cell death involves activation of a caspase 9/mitochondria dependent pathway and does not activate caspase-8 , which suggests it may not play a signi®cant cell death receptor role in bFGF-induced cell death. Alternatively up-regulation of p75 may induce an apoptotic signal through activation of pathways generally characterized as stress response signals e.g. jun N-terminal kinase (JNK) (Dobrowsky and Carter, 2000) . We are currently investigating these possibilities.
A673 and SK-ES1 ESFT cells do not die when exposed to bFGF (Westwood, PhD thesis 2001) and do not express wild-type p53 protein, re¯ecting a 2-bp insertion between codons 116 and 119 leading to the formation of a stop codon 6-bp further downstream in A673 cells (Kovar et al., 1993) and a mis-sense mutation at codon 176 of p53 in SK-ES1 cells. This suggests that wild-type p53 is important for the induction of cell death in ESFT cells after exposure to bFGF, consistent with arrest of cells at the G 1 checkpoint (O'Connor et al., 1997) , stabilization of p21 (el-Deiry, 1998) and suppression of Bcl-2 (Reed, 1998) . However, in this study we have identi®ed coding mutations in ESFT cell lines that do and do not die following exposure to bFGF. In particular, bFGFinduces death in SK-N-MC cells (Sturla et al., 2000) which do not express p53 at the protein level, re¯ecting deletion of exons 2, 3 and 4 of the p53 gene. Therefore p53 status does not distinguish between ESFT cell lines susceptible to bFGF-induced cell death, and expression of wild-type p53 protein is not essential for bFGFinduced cell death. These data are consistent with that of Kovar et al. (2000) establishing that the transcriptional activity of p53 is not sucient to initiate a caspase cascade and activate cell death. Although mutations of p53 are extremely rare in ESFT (Kovar et al., 1993; Radig et al., 1998) , they would not signi®cantly impact on the induction of cell death by bFGF.
In the current study we have shown down-regulation of Bcl-2 in TC-32 and TTC-466 cell lines following induction of cell death by bFGF. Furthermore, bFGF had no eect on expression of Bcl-2 in non-responsive A673 cells; however resistance to bFGF-induced cell death does not appear to be associated with the level of Bcl-2 expressed since basal levels are the same in bFGF-responsive and non-responsive cells. This is in contrast to inhibition of proliferation and induction of apoptosis in the MCF-7 breast cancer cell line which appears to occur through a down-regulation of Bcl-2 and an increase in Bax protein levels (Wang et al., 1998) , consistent with the cell death inhibitor and promoter function of these prototype Bcl-2 proteins.
Parameters of mitochondrial dysfunction that occur during cell death include loss of mitochondrial membrane potential (Dc m ) and release of cytochrome c from the mitochondrial inter-membrane space (Green and Reed, 1998) . The Dc m of TC-32 and TTC-466 cells was lost after 24 h treatment with bFGF, although cytochrome c release from the mitochondria into the cytosol was not detected. This is consistent with the observation that procaspase-9 is not cleaved to its active form in TC-32 or TTC-466 cells after treatment with bFGF, and may re¯ect the protective activity of Bcl-X L reported to induce a block in cytochrome c release but not mitochondrial depolarization (Johnson et al., 2000) . Since it has been suggested that only relatively sustained pore-openings result in the release of cytochrome c (Petronilli et al., 2001) , loss of Dc m in ESFT cell lines may re¯ect permeability transition pore (PTP) openings of shorter duration. Some studies have demonstrated that cytochrome c release can occur independently of a decrease in Dc m (Finucane et al., 1999) , and vice versa. For example cell death may be induced by novel chemotherapeutic agents such as avopiridol following depolarization of mitochondria in the absence of cytochrome c release, although this usually occurs in caspase-8 defective cells (Achenbach et al., 2000) . Procaspase-8 is localized in mitochondria, from which it is released into the cytosol following induction of cell death (Qin et al., 2001) . Consequently, the decrease in Dc m in the TC-32 and TTC-466 cells after exposure to bFGF may be accompanied by the release of procaspase-8 from the mitochondria into the cytosol, resulting in its cleavage and activation. Whether other proteins that translocate from mitochondria after a death stimulus (e.g. Apaf-1 and Smac) play a role in bFGF-induced cell death is not clear and requires further investigation.
bFGF-induced cell death of ESFT is associated with cell cycle changes consistent with accumulation of cells in G 1 , characterized by a decrease in expression of PCNA and phosphorylation of pRb1. In the TC-32 cells p21 levels were also increased after treatment with bFGF, suggesting a potential mechanism for pRb1 activation (Ono et al., 2000) . However, this is unlikely to be the sole mechanism of pRb1 activation as bFGF also activates pRb1 in the p21 negative TTC-466 cells. Furthermore, expression of p21 has been associated with increased survival of ESFT (Javelaud et al., 2000) and colorectal (Gorospe et al., 1996) cancer cell lines. Cyclin A levels were decreased in cells that died following exposure to bFGF, consistent with the hypothesis that these cells do not pass through the G 1 checkpoint and therefore cannot undergo DNA replication (Wang et al., 1997) . Previous studies have also shown growth inhibition in breast cancer (Wang et al., 1997; Johnson et al., 1998) or ESFT (Schweigerer et al., 1987; Smits et al., 2000) cells following treatment with bFGF. In MCF-7 cells this is associated with G 1 arrest, regulated by an increase in p21 mRNA and protein, dephosphorylation of the pRb1 protein and a decrease in cyclin A levels (Wang et al., 1997) . This is largely consistent with our data. However, negative growth regulation of the SK-N-MC cell line is reported to involve arrest of cells at G 2 (Smits et al., 2000) , which is in direct contrast to the ®ndings of Wang et al. (1997) and our study. The SK-N-MC cell line contains the t(11.22)(q24.q12) gene rearrangement, characteristic of ESFT. However, this line was originally classi®ed as a neuroblastoma (Biedler et al., 1973) , therefore genotypic or phenotypic cell variation may explain the dierent growth-factor sensitive cell cycle checkpoints.
In conclusion, bFGF-induced cell death of the TC-32 and TTC-466 ESFT cell lines is mediated through the activation of initiator (caspases-2, -8, -10) and eector (caspases-3, -6, -7) caspases in a p53 independent manner. Induction of death by bFGF does not require release of cytochrome c from mitochondria or activation of procaspase-9, suggesting bFGF-induced cell death may occur through a cell death receptor and/or stress-activated kinase pathway. Up-regulation of the TNF death receptor p75 is consistent with this hypothesis, although this requires further investigation. Further insight into the pathways involved in the induction of cell death by bFGF may be exploited to modulate the behaviour of ESFT, and provide an opportunity for therapeutic initiatives.
(b)
Figure 8 Induction of cell death by bFGF is accompanied by disruption of G1/S cell cycle progression. (a) TC-32, TTC-466 and A673 cells were harvested by trypsination, ®xed in 70% ethanol, treated with DNAse-free RNAse (50 mg/ml) and labelled with propidium iodide (10 mg/ml). Acquisition and analysis was carried out using FACScan and CellQuest TM software. Percentages represent the proportion of cells found in the G 1 phase of cell cycle. The results shown are representative of three separate experiments for each cell line. (b) TC-32 and A673 cells were synchronized by serum starvation (0.5% FCS for 48 h) and treated with bFGF (10 ng/ml) for 24, 48 or 72 h. Cell lysates were separated by SDS ± PAGE, transferred to a nitrocellulose solid support and immunoblotted for PCNA, pRb1, p21, and cyclin A. Proteins were detected by ECL. The results shown are representative of four separate experiments for each cell line. Silver stain was used to demonstrate equal quality and loading of protein lysates (results not shown). Immunoblotting controls were also carried out with no primary antibody (results not shown). +=treated with bFGF (10 ng/ml), 7=untreated control; +ve control for PCNA, pRB1 and cyclin A=Jurkat cell lysate; +ve control for p21=human foreskin ®broblasts; 7ve control for all target proteins=Rama temporaria skeletal muscle
Materials and methods

Cell lines
All incubations and treatments, unless otherwise stated, were carried out at room temperature.
The substrate adherent TC-32, RD-ES and TTC-466 cells were grown in RPMI 1640 media (Sigma, Poole, Dorset, UK) containing 10% FCS (SeraLab, Crawley Down, Sussex, UK); media for TTC-466 cells was supplemented with 10% conditioned media. A673, HFF and NIH-3T3 cells were grown in Dulbecco's Modi®ed Eagle's Media (DMEM) (Sigma) and 10% FCS. SK-ES1 cells were grown in McCoys media (Sigma) plus 15% FCS and SK-N-MC cells in DMEM F12 (Sigma) plus 10% FCS. Jurkat cells grew as a suspension culture in RPMI 1640 plus 10% FCS. All cell lines were purchased from the ATCC, except for the TC-32 and RD-ES cells which were a kind gift from Dr J Toretsky (Division of Pediatrics, University of Maryland, USA), and the TTC-466 cells a kind gift from Dr P Sorenson (British Columbia Children's Hospital, Vancouver, Canada).
Viable cell counts
Cells (2610 5 /well) seeded in Primeria 6-well plates (Fahrenheit, Morley, Leeds, UK) were maintained for 24 h, and then treated with bFGF (10 ± 40 ng/ml; w/v) (Sigma) for up to 72 h. Control cultures contained no bFGF. Cells were harvested by trypsinization, trypan blue (0.2%; ICN Biochemicals, Basingstoke, Hampshire, UK) was added to a single cell suspension and viable cell number counted using a Neubauer haemocytometer.
Electron microscopy
After treatment with bFGF (20 ng/ml) for 24, 48 and 72 h cells were harvested and centrifuged at 81 g for 4 min to form a soft pellet. Cell pellets were ®xed in 2.5% (v/v) gluteraldehyde in Sorenson's buer (0.16 M disodium hydrogen orthophosphate (BDH, Poole, Dorset, UK), 0.04 M sodium dihydrogen phosphate (BDH), pH 7.4) for 1 h, followed by four 20 min washes with Sorenson's wash buer. The cell pellets were post-®xed in 1% osmium tetra oxide in Sorenson's buer for 30 min, washed and dehydrated through ethanol gradients. After washing in propylene oxide pellets were in®ltrated with araldite/ propylene oxide (1 : 1) overnight, and then with araldite pre-warmed to 608C for 10 min (63). After embedding in resin and polymerization, sections (80 mm) were cut, mounted on gold grids and stained with a saturated solution of uranyl acetate in methanol for 4 min. After washing in methanol, sections were stained with Reynold's lead citrate for 4 min, washed, sections cut with a diamond knife and examined by light and electron microscopy.
Annexin V and PI labelling
Treated (bFGF 20 ng/ml for 48 or 72 h) and untreated cells were labelled with annexin V (1 mg/ml; Alexis, Nottingham, UK) and propidium iodide (1 mg/ml; Sigma) for 30 min in the dark. The samples were then analysed using FACScan ow cytometry (Becton Dickinson, Oxford, UK) and CellQuest TM software. A minimum of three independent experiments was carried out for each condition. Data is presented as mean percentage of each quadrant.
Preparation of cell extracts for detection of phosphorylated proteins
Cells (2610 6 ) were seeded in a 60 mm petri dish, allowed to adhere overnight and either untreated or treated with bFGF (10 ng/ml) for 2 ± 10 min. Petri dishes were placed on ice, washed once with 2 ml ice-cold 10 mM MgCl 2 in PBS and overlaid with 500 ml ice-cold lysis buer (50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EGTA, 1 mM DTT, 10 mM MgCl 2 , 1% Triton x-100, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM sodium orthovanadate, 25 mM sodium uoride). The monolayer was disrupted using a cell scraper and the lysate centrifuged at 11 600 g for 10 min at 48C. Protein concentration was determined using the Bio-rad DC Protein Assay (Bio-rad, Hemel Hempstead, Herts, UK).
Activated Ras (GST-RBD) assay
Cell lysate (600 mg) was incubated with 30 ml of GST-RBD or GST sepharose 50% (v/v) slurry in lysis buer on a rotating wheel for 1 h at 48C. Sepharose was pelleted at 11 600 g for 30 s at 48C, washed three times in 1 ml of ice-cold wash buer (10 mM MgCl 2 , 0.1% (v/v) Triton X-100 in PBS) and resuspended in 30 ml of 16SDS sample buer (100 mM Tris.HCl (pH 6.8), 200 mM DTT, 4% SDS, 0.2% bromophenol blue, 20% glycerol). Samples were heated at 1008C for 3 min and the supernatant analysed by immunoblotting using antibodies to pan-Ras (Table 4) . Plasmid pGEX-RBD was a kind gift from Dr Stefan WennstroÈ m (ICRF, Lincoln's Inn Fields, London, UK).
Immunopreciptation of FGFr1
Cell lysate (200 mg) was diluted in lysis buer and 10% (w/v) SDS to a ®nal volume of 500 ml and 0.1% (w/v) SDS. Protein was denatured for 3 min at 1008C and immediately placed on ice. Antibodies to FGFr1 (Table 4 ) and 30 ml of protein A sepharose CL-4B (50% (v/v) slurry in 20 mM sodium phosphate, pH 7.0; Pharmacia) were added to the cooled lysate and incubated overnight with rotation at 48C. Sepharose was pelleted by centrifugation at 11 600 g for 30 s, the supernatant removed and the pellet resuspended in 1 ml of ice-cold PBS containing 0.1% (w/v) SDS; this was repeated twice. Supernatant was discarded and the sepharose resuspended in 30 ml of 16SDS sample buer. Immunoprecipitated samples were separated by 8% SDS ± PAGE and transferred to nitrocellulose. An immunoprecipitation control with no antibodies to FGFr1 was used to determine nonspeci®c binding of proteins to the sepharose. Phosphorylated proteins immunoprecipitated by FGFr1 antibodies were detected by immunoblotting (Table 4) ; membranes were blocked in 1% (w/v) BSA in TTBS and both primary and secondary antibody were diluted in 0.1% (w/v) BSA in TTBS. Control blots were probed with the secondary antibody alone. Proteins were detected using enhanced chemiluminiscence (ECL; Amersham, UK).
Immunodetection of immobilized proteins
Protein extracts were prepared from cells and Rama temporaria skeletal tissue. Cells were added directly to lysis buer (10 mM Tris.HCl pH 7.4; 1% SDS and 1 mM sodium orthovanadate), extracts boiled for 5 min, and viscous samples passed through a 26-gauge needle. Tissues were minced with scissors, the lysis buer added and extracts glass ± glass homogenized, before microwaving for 10 s and centrifugation to remove insoluble material. The protein concentration of extracts was estimated using the Bio-rad DC Protein Assay. Samples were size-separated using SDS ± PAGE. For the detection of the unphosphorylated and phosphorylated forms of pRb1 and ERK proteins, a low bisacrylamide was used (200 : 1 acrylamide: N,'N-methlene bisacrylamide) (Flowgene, Sittingbourne, Kent, UK). Rainbow Molecular Weight Markers (3 ml; Invitrogen, Leek, Netherlands) were used to estimate protein size, and loading was con®rmed using the Pharmacia Silver Stain kit (Pharmacia).
Membranes were blocked in 5% (w/v) non-fat dried skimmed milk (Marvel) in Tween 20-Tris-buered Saline (TTBS) (20 mM TrisHCl pH 7.5, 500 mM NaCl, 0.05% (v/v) Tween 20 (Sigma)) for 2 h and then incubated with primary mouse monoclonal antibodies diluted in 1% (w/v) non-fat dried milk in TTBS for 2 h (Table 4) , washed and incubated with anti-mouse IgG horseradish peroxidase (HRP)-conjugated secondary antibody (1 : 1000; Sigma) for 1 h. Control blots were probed with the secondary antibody alone. Proteins were detected using enhanced chemiluminiscence (ECL; Amersham).
Caspase activity
The general caspase inhibitor Z-VAD-FMK and Trypan blue exclusion, and CaspaTag TM Fluorescein Caspase Activity kit (Intergen, Oxford, UK) and¯ow cytometry were both used to detect active caspases. The general caspase inhibitor was added to cells under normal growth conditions, 2 h prior to treatment with bFGF (10 ng/ml) for up to 72 h. Cells with no inhibitor or bFGF, with only bFGF or only inhibitor added were included as controls. The caspase probe, FAM-VAD-FMK, was added directly to the ESFT cell suspensions (1610 6 cells/ml PBS) which were incubated for 45 min at 378C under 95% air; 5% CO 2 in the dark. The cells were washed, propidium idodide added and the cells analysed immediately by¯ow cytometry and CellQuest TM software.
Specific caspase activation
Caspase activity was assayed using the chromophore paraNitroanaline (pNA) attached to the speci®c caspase substrate sequence. Cleavage of the substrate resulted in the release of the chromogen. Caspase activity was measured by a change in absorbance at 405 nm, 2 h after addition of the substrate. Cells were treated with bFGF (10 ng/ml) for 48 or 72 h, washed in PBS and resuspended in 200 ml ice-cold lysis buer (50 mM HEPES pH 7.4, 100 mM NaCl, 0.1% CHAPS, 1 mM DTT, 100 mM EDTA). After 5 min on ice, samples were centrifuged (10 000 g610 min at 48C) and the supernatant (cytosolic extract) retained for analysis. Protein concentration was determined as above and extracts adjusted to a concentration of 2 mg protein/ml. Activity was measured, using pNA-conjugated substrate at a ®nal concentration of 200 mM, as a change in absorbance at 405 nm at 378C in 96-well¯at-bottomed microtiter plates according to manufacturers instructions. The assay and all reagents were equilibrated to 378C. Chromophore, cell extract and wash buer only controls were included.
Cellular fractionation
This subcellular fractionation procedure was adapted from Koya et al. (2000) . Brie¯y, TC-32, TTC-466 and A673 cells were treated with bFGF (10 ng/ml) for 24, 48 and 72 h. Cells (non-adhered and adhered) were washed in PBS and harvested by cell scraping. The cell pellet was resuspended in iso-osmotic buer (0.3 M sucrose, 10 mM Tris.HCl (pH 7.5) and 1 mM EDTA) and incubated on ice for 5 min. The cell suspension was homogenized using a glass ± glass homogenizor and centrifuged at 1000 g for 10 min at 48C. The supernatant was retained and the pellet was discarded (nuclear fraction). The supernatant was centrifuged at 8000 g for 10 min at 48C, and the supernatant was again retained for further fractionation. The pellet (mitochondrial fraction) was subjected to repeated centrifugation twice (8000 g for 10 min at 48C), with the mitochondrial pellet being resuspended in iso-osmotic buer between each fractionation step. The supernatant from this repeated centrifugation was discarded. The mitochondrial pellet was then resuspended in iso-osmotic buer. The supernatant retained from the initial mitochondrial fractionation was centrifuged at 100 000 g for 1 h at 48C, with the supernatant from this fractionation step representing the cytoplasmic fraction.
Detection of mitochondrial transmembrane potential
Mitochondrial transmembrane potential (Dc m ) is required for the import of tetramethylrhodamine ethyl ester percholate (TMRE; Molecular Probes, Leiden, Netherlands) into the mitochondria. In apoptotic cells, this transmembrane potential is lost and TMRE is only detected outside the mitochondria. TC-32, TTC-466 and A673 cells were pulsed with TMRE (50 nM) during the last 30 min of each incubation with bFGF (10 ng/ml). The ESFT cell lines were washed with PBS before harvesting by cell scraping. Cells were resuspended in PBS (1610 6 cells/ml) supplemented with 15 nM TMRE, and cell suspensions analysed immediately by¯ow cytometry and CellQuest TM software.
Characterization of p53 gene
Primers for ampli®cation of the p53 gene were designed for all 11 exons, with M13 tails to allow incorporation of uorescence using a modi®ed universal labelling approach (Schuelke, 2000) and for two sets of Long-PCR primers to scan for deletion across the whole gene. Exonic primers were optimized using modi®ed touchdown programmes, allowing the identi®cation of a generic cycling pro®le capable of amplifying all fragments. Conditions for ampli®cation using the Long-PCR primers were optimised by standard procedures.
Ampli®ed exonic products were subject to Fluorescent Single Stranded Conformation Polymorphism (F-SSCP) analysis at 18, 22 and 358C on an ABI3100 Genetic Analyser (Applied Biosystems, Warrington, UK). Band-shifts were identi®ed using Genotype analysis software (Applied Biosystems). Samples showing band-shifts under at least one of the experimental conditions were sequenced using the ABI3100 and a Big-Dye Terminator Ready Reaction kit (Applied Biosystems), according to the manufacturers protocol. Using Sequence navigator (Applied Biosystems) sequences were aligned and analysed by comparison with the published wildtype p53 sequence.
Long-PCR was performed using Extensor Hi-Fidelity PCR Master Mix (Abgene, Epsom, UK) and products run out on agarose gels (0.8%), stained with ethidium bromide and visualized under UV-light. Primer sequences, ampli®cation and analysis conditions are available on request.
Cell cycle profile
Cells were synchronized by serum starvation (normal growth media supplemented with 2 mM glutamine and 0.5% FCS) for 48 h, and harvested to form a cell suspension. This suspension was split into two, one propidium iodide-free and one labelled with propidium iodide. Cells were ®xed in ethanol (70%) on ice for 1 h, pelleted by centrifugation (403 g65 min) and the cell pellets resuspended and incubated in 250 ml PBS and 50 mg/ml DNAse-free RNAse (Boehringer Mannheim, Lewes, East Sussex, UK) for 2 h. Propidium iodide (10 mg/ml in PBS) was added to one of the FACScan (Becton Dickinson, Cowley, Oxford, UK)¯ow tubes and samples analysed using CellQuest TM software. The eect of bFGF (10 ng/ml) on cell cycle pro®le was examined after incubation for 24, 48 and 72 h. Controls with no bFGF added were included.
